DE10323759A1 - Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen - Google Patents
Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen Download PDFInfo
- Publication number
- DE10323759A1 DE10323759A1 DE10323759A DE10323759A DE10323759A1 DE 10323759 A1 DE10323759 A1 DE 10323759A1 DE 10323759 A DE10323759 A DE 10323759A DE 10323759 A DE10323759 A DE 10323759A DE 10323759 A1 DE10323759 A1 DE 10323759A1
- Authority
- DE
- Germany
- Prior art keywords
- minerals
- weight
- grain size
- dolomite
- medicinal product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 15
- 201000011510 cancer Diseases 0.000 title claims abstract description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 34
- 239000011707 mineral Substances 0.000 claims abstract description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- 235000013339 cereals Nutrition 0.000 claims description 19
- 239000010459 dolomite Substances 0.000 claims description 17
- 229910000514 dolomite Inorganic materials 0.000 claims description 17
- 235000013312 flour Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 229910021536 Zeolite Inorganic materials 0.000 claims description 10
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000010457 zeolite Substances 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- 229940126601 medicinal product Drugs 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 239000004575 stone Substances 0.000 claims description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 9
- 239000008158 vegetable oil Substances 0.000 claims description 9
- 239000010453 quartz Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 239000001923 methylcellulose Substances 0.000 claims description 7
- 235000010981 methylcellulose Nutrition 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 6
- 235000019485 Safflower oil Nutrition 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- -1 polydimethylsiloxane Polymers 0.000 claims description 3
- 235000005713 safflower oil Nutrition 0.000 claims description 3
- 239000003813 safflower oil Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 14
- 229910052710 silicon Inorganic materials 0.000 description 14
- 239000010703 silicon Substances 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000000227 grinding Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 5
- 239000000084 colloidal system Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 238000013021 overheating Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 239000011856 silicon-based particle Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000011034 rock crystal Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10323759A DE10323759A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
| EP04733527A EP1628671A1 (de) | 2003-05-22 | 2004-05-18 | Steinmehl, insbesondere dolomitsteinmehlheilmittel , zur behandlung von krebserkrankungen |
| JP2006529602A JP2006528210A (ja) | 2003-05-22 | 2004-05-18 | 岩粉、好適にはドロマイト岩粉をベースとした癌治療のための薬 |
| CNA2004800140425A CN1795002A (zh) | 2003-05-22 | 2004-05-18 | 用于治疗癌症的基于岩石粉、更具体是白云石粉的药物 |
| AU2004243523A AU2004243523A1 (en) | 2003-05-22 | 2004-05-18 | Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases |
| PCT/DE2004/001047 WO2004105777A1 (de) | 2003-05-22 | 2004-05-18 | Steinmehl, insbesondere dolomitsteinmehlheilmittel, zur behandlung von kresbserkrankungen |
| CA002525908A CA2525908A1 (en) | 2003-05-22 | 2004-05-18 | Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases |
| US10/558,099 US20060251738A1 (en) | 2003-05-22 | 2004-05-18 | Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases |
| RU2005140098/15A RU2005140098A (ru) | 2003-05-22 | 2004-05-18 | Мука из горной породы, в частности, лекарственное средство на основе доломитовой муки, для лечения раковых заболеваний |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10323759A DE10323759A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10323759A1 true DE10323759A1 (de) | 2004-12-16 |
Family
ID=33441300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10323759A Withdrawn DE10323759A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060251738A1 (https=) |
| EP (1) | EP1628671A1 (https=) |
| JP (1) | JP2006528210A (https=) |
| CN (1) | CN1795002A (https=) |
| AU (1) | AU2004243523A1 (https=) |
| CA (1) | CA2525908A1 (https=) |
| DE (1) | DE10323759A1 (https=) |
| RU (1) | RU2005140098A (https=) |
| WO (1) | WO2004105777A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006122543A1 (de) * | 2005-05-18 | 2006-11-23 | Tihomir Lelas | Mikronisierte mineralische materialien und deren herstellung |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070009809A1 (en) * | 2005-07-08 | 2007-01-11 | Krekeler Mark P | Synthetic Nanoparticle Soil Materials |
| KR101199895B1 (ko) | 2011-11-14 | 2012-11-09 | 권태동 | 천연 광물 및 이의 용해물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물 |
| KR101199897B1 (ko) | 2011-11-14 | 2012-11-09 | 권태동 | 천연 광물 및 이의 용해물을 유효성분으로 함유하는 암 예방 및 치료용 조성물 |
| DE102013013029A1 (de) * | 2013-08-05 | 2015-02-05 | Ernst Fekete | Lobbyist-Zellschutz PNI (Psychoneuroimmunium) |
| CN104606261B (zh) * | 2015-03-05 | 2018-02-09 | 潘友长 | 一种沸石药物组合物及其制备方法和用途 |
| RU2629338C1 (ru) * | 2016-08-26 | 2017-08-28 | Алам Джан | Фармацевтическая композиция для стабилизации гомеостаза и купирования патологических процессов в организме и инъекционная лекарственная форма этой композиции |
| KR101996383B1 (ko) | 2017-12-01 | 2019-07-04 | (주)카데시인코퍼레이션 | 퓨리톤을 유효성분으로 포함하는 항암용 조성물 |
| CN108403755A (zh) * | 2018-05-03 | 2018-08-17 | 北京胜泰生物医药科技有限公司 | 一种沸石药物的组合、制备及用途 |
| US20230225386A1 (en) * | 2021-12-30 | 2023-07-20 | H2 Universe Llc | Hydrogen-generating composition for dietary and agricultural applications |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU200933B (en) * | 1988-12-22 | 1990-09-28 | Jozsef Markus | Process for producing pharmaceutical composition for profilacting and treating osteoporosis |
| DE19530882A1 (de) * | 1995-08-11 | 1997-02-13 | Thomas Dr Ing Loeser | Arzneimittel zur Vorbeugung, Begleittherapie und Heilung von Geschwulstkrankheiten |
| DE19603477A1 (de) * | 1996-01-31 | 1997-08-07 | Klaus Dr Med Reuter | Tumormittel |
| DE19780248D2 (de) * | 1996-03-25 | 1999-03-11 | Bauer Wulf Dr | Heilmittel zur äußerlichen Anwendung und Verwendung einer wässrigen Öl-Emulsion für ein derartiges Heilmittel |
| DE19750328A1 (de) * | 1997-11-13 | 1999-05-20 | Klaus Dr Med Reuter | Tumormittel |
| US6251439B1 (en) * | 1998-12-16 | 2001-06-26 | Trustee Of The Dartmouth College | Composition and method for reducing the risk of carcinogenesis |
| EP1316530B1 (de) * | 1999-04-26 | 2004-12-15 | Tihomir Lelas | Mikronisierte Zoelithe zur Verwendung als pharmazeutisches Mittel |
| EP1129715A1 (de) * | 2000-02-25 | 2001-09-05 | Werner Dr. Reichen | Anwendung von Magnesium, Kalzium und Silizium zur Heilung verschiedener Krankheiten und zum allgemeinen Wohlbefinden |
| JPWO2002024167A1 (ja) * | 2000-09-19 | 2004-01-29 | 第一製薬株式会社 | 医薬組成物 |
| JP2003063951A (ja) * | 2001-08-23 | 2003-03-05 | Nonogawa Shoji Kk | 錠剤及びその製造方法 |
| DE10323758A1 (de) * | 2003-05-22 | 2004-12-16 | Bauer, Wulf, Dr. | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
-
2003
- 2003-05-22 DE DE10323759A patent/DE10323759A1/de not_active Withdrawn
-
2004
- 2004-05-18 AU AU2004243523A patent/AU2004243523A1/en not_active Abandoned
- 2004-05-18 US US10/558,099 patent/US20060251738A1/en not_active Abandoned
- 2004-05-18 CA CA002525908A patent/CA2525908A1/en not_active Abandoned
- 2004-05-18 CN CNA2004800140425A patent/CN1795002A/zh active Pending
- 2004-05-18 WO PCT/DE2004/001047 patent/WO2004105777A1/de not_active Ceased
- 2004-05-18 EP EP04733527A patent/EP1628671A1/de not_active Withdrawn
- 2004-05-18 RU RU2005140098/15A patent/RU2005140098A/ru unknown
- 2004-05-18 JP JP2006529602A patent/JP2006528210A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006122543A1 (de) * | 2005-05-18 | 2006-11-23 | Tihomir Lelas | Mikronisierte mineralische materialien und deren herstellung |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004243523A1 (en) | 2004-12-09 |
| RU2005140098A (ru) | 2006-08-10 |
| CN1795002A (zh) | 2006-06-28 |
| EP1628671A1 (de) | 2006-03-01 |
| US20060251738A1 (en) | 2006-11-09 |
| JP2006528210A (ja) | 2006-12-14 |
| WO2004105777A1 (de) | 2004-12-09 |
| CA2525908A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2320754B1 (de) | Mikroemulsion | |
| US20220331344A1 (en) | Oral formulations of psychotropic macrofungus botanical extracts with mouthfeel experience enhancers | |
| US11596618B2 (en) | Oral cannabinoid delivery formulations with mouthfeel experience enhancers | |
| DE10323759A1 (de) | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen | |
| CN1243434A (zh) | 注入堆积密度为0.28～0.38g/ml的含有布地奈德的吸入用新配方 | |
| EP3151842A1 (de) | Silikonölhaltige nasal anzuwendende formulierungen | |
| DE60224202T2 (de) | Erhöhte löslichkeit von flavanolignanzubereitungen | |
| DE10323758A1 (de) | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen | |
| DE60119976T2 (de) | Thixotropes nasenspray | |
| Mansingh et al. | Herbal nanoparticles: a commitment towards contemporary approach | |
| DE102017010930A1 (de) | Topische Zubereitungen | |
| DE69100954T2 (de) | Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung. | |
| JP2006528210A5 (https=) | ||
| WO2022219166A1 (en) | Combination preparation containing resveratrol | |
| DE60022689T2 (de) | Pharmazeutische desinfektionsmittel, die usninsäure und ein ätherisches öl enthalten | |
| EP1911464B1 (de) | Gelartiges Basenpräparat auf Basis ätherischer Ölmischungen zur dermalen und transdermalen Anwendung | |
| Arhewoh et al. | A study on the interaction between metformin and constituents of a commercial herbal product. | |
| Kalliantas et al. | The nanostructure character of Arnica montana as ultra high diluted succussed solution medicinal product. Recent advances and prospects | |
| EP0256353A2 (de) | Pharmazeutikum zur Therapie einer schlechten Absorption von Nahrungsmitteln und von Oral einzunehmenden Medikamenten | |
| WO2006108414A2 (de) | Mittel zur therapie und prophylaxe von hauterkrankungen | |
| Meng et al. | Characterization, cytotoxicity and anti-human renal cell carcinoma efficacies of copper nanoparticles green-synthesized by Panax ginseng | |
| DE202005020103U1 (de) | Nahrungsergänzungsmittel | |
| DE4129874C1 (en) | Granulating humic acids and/or cpds. - by mixing with granulating fluid for wet or moist granulation, then pressing through matrix | |
| EP2509613A1 (de) | Zusammensetzung zur behandlung von magen- und darmbeschwerden | |
| EP1354591B1 (de) | Topische Zusammensetzung enthaltend Rauchagglomerate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |